市场监管总局有关负责人表示，未来将强化执法办案，完善制度规则，提升执法能力，加强统筹协调， 维护公平公正市场秩序。 全年办结垄断协议和滥用市场支配地位案件11件、审结经营者集中案件643件；聚焦医药、供水、供 气、金融数据和互联网平台等重点领域，反垄断执法成效显著；已与我国签署协定的23个自由贸易区 中，19个在协定中含有竞争章节或竞争条款，占比达82.6%……国家市场监督管理总局近日发布的《中 国反垄断执法年度报告(2024)》(以下简称"报告")，给出了我国反垄断执法工作的年度"成绩单"。 统筹纠治市场垄断和行政性垄断 报告显示，2024年市场监管部门统筹纠治市场垄断和行政性垄断，系统加强事前事中事后全链条监管， 推动反垄断工作迈上新台阶，竞争政策基础地位巩固强化，竞争监管执法效能进一步提升。 ——制止垄断协议和滥用市场支配地位执法扎实推进。全年办结垄断协议和滥用市场支配地位案件11 件，对1起拒绝、阻碍调查案件作出行政处罚，罚没金额1.19亿元。 ——经营者集中监管质效稳步提升。全年审结经营者集中案件643件，无条件批准623件。 ——纠治地方保护和市场分割力度明显加大。全年立案查处滥用行政权力排除、限 ...

针对香港如何发挥国际化双向门户作用，张曼莉提到，香港通过"跨境数据标准合同" "港澳药械通"等政策创新，为大湾区企业营造与国际接轨的营商环 境。例如，"港澳药械通"允许指定大湾区医院使用部分在香港已上市但未在内地注册的药械，有助加速全球医药企业在内地的临床试验与注册流程。 此外，张曼莉表示，香港在人工智能与机器人技术、生命科学、新能源及新材料等领域的研发基础，配合产业巨头如宁德时代（03750.HK）等设立的国际 研发中心，正推动大湾区在全球科技前沿领域占据先机。 张曼莉强调，香港将继续担当大湾区的国际研发中试枢纽、人才门户与资本连接器，通过强化"政产学研投"协同，推动大湾区成为创新驱动发展的全球典 范。 香港将继续担当大湾区的国际研发中试枢纽、人才门户与资本连接器 6月6日，博鳌亚洲论坛国际科技与创新论坛首次于香港举行会议。香港创新科技及工业局副局长张曼莉出席会议，围绕"香港科创政策如何助力大湾区企业 发展并担当'引进来、走出去'科技门户"等议题，分享香港在大湾区创新集群中的独特角色与策略。 张曼莉指出，凭借"一国两制"优势，香港正以河套深港科技创新合作区为核心载体，通过政策创新打破跨境障碍，吸引全球创科资 ...

Core Points - The National Anti-Monopoly Bureau released the "2024 Annual Report on Anti-Monopoly Law Enforcement in China," highlighting the enforcement actions taken against monopolistic practices and market dominance abuse [1][2] Summary by Categories Anti-Monopoly Enforcement - In 2024, 11 cases of monopoly agreements and abuse of market dominance were concluded, with a total penalty of 119 million yuan [2] - The report emphasized ongoing investigations into monopolistic agreements, particularly in the motor vehicle inspection sector, with significant penalties imposed on multiple companies [3] Digital Economy Regulation - The report noted the ongoing normalization of anti-monopoly regulation in the digital economy, with specific focus on Alibaba and Meituan's compliance with rectification measures [4] Operator Concentration Oversight - The average review time for operator concentration cases was reduced to 24.7 days, down by one day from the previous year, with 643 cases processed in total [5][6] - The manufacturing sector accounted for the highest number of concentration cases, with 213 cases, representing 34% of the total [5] Administrative Monopoly - A total of 72 cases of abuse of administrative power to exclude or restrict competition were filed, with 57 cases concluded [8] - The report highlighted efforts to combat local protectionism and market segmentation, with a significant increase in the number of cases filed and concluded compared to the previous year [8] Industry Focus Areas - The anti-monopoly enforcement agency is paying close attention to the cultural entertainment ticketing market, patent database market, and the new energy vehicle charging and swapping industry [9] - The report suggested enhancing market regulation in the new energy vehicle charging sector and addressing issues related to pricing and service standards [10]

2025.06. 06 本文字数：2157，阅读时长大约4分钟 作者 | 第一财经 吴斯旻 医药行业关系民生且垄断高发，一直是我国反垄断执法重点。而反垄断监管执法的加强和改进及公平 竞争制度的构建和完善，则关乎本土药企和跨国药企投资、发展的制度性成本。 6日，市场监管总局（国家反垄断局）发布《中国反垄断执法年度报告（2024）》（下称"报 告"）。对于过去一年的执法成效，报告称，民生领域反垄断执法专项行动纵深推进。集中全系统骨 干力量查办医药领域系列重大专案，始终保持高压态势，纠治行业竞争乱象，推动涉案药品降价 62%。 根据报告，中央和地方的反垄断监管机构也对医药经营主体的收并购行为和行政权力排除、限制竞争 行为，予以重点关注。 一名地方反垄断和公平竞争审查专家库专家、医药反垄断领域资深律师在接受第一财经采访时表示， 近年来，药品领域的垄断行为多发频发，垄断行为多样、复杂且隐蔽，造成后果严重，垄断行为的实 施主体还可能存在主观故意性和"屡教屡犯"问题。 在此背景下，根据报告，去年医药反垄断执法保持"高压"并呈现出"标准兼治"的三个特征：一是执 法效果显著，推动当年新立案案件的涉案药品大幅降价；二是推动法治建 ...

Group 1 - Yatai Group signed a strategic cooperation agreement with Xuanfeng Technology, focusing on long-term mutual benefits and cooperation in core business areas [1][2] - The partnership aims to develop a full-chain renewable energy business, upgrading Yatai's building materials production base for low-carbon operations [2][3] - Both companies will collaborate on power management integrated circuits and related components to enhance power conversion and transmission efficiency [2][3] Group 2 - Yatai Group has a diversified industrial structure, including building materials, real estate, and pharmaceuticals, with a focus on circular economy and digital transformation [2][3] - The real estate sector encompasses development, construction, and property services, with a national layout and a focus on modern building practices [3] - The pharmaceutical sector includes a complete health industry chain, with smart manufacturing and a wide range of health management services [3] Group 3 - Xuanfeng Technology is a leader in vertical axis wind power generation, with a commitment to zero-carbon energy and a presence in over 10 countries [1] - The company has established three major R&D centers in the US, Germany, and China, and operates over 1,000 service points in China [1] - The collaboration will also explore opportunities in biotechnological projects related to precision medical testing, supporting China's health strategy [2][3]

证券研究报告 | 2025年06月06日 热点追踪周报 由创新高个股看市场投资热点（第 197 期） 乘势而起：市场新高趋势追踪：截至 2025 年 6 月 6 日，上证指数、深证 成指、沪深 300、中证 500、中证 1000、中证 2000、创业板指、科创 50 指数 250 日新高距离分别为 2.99%、11.41%、8.98%、8.98%、6.94%、4.25%、 20.03%、12.00%。中信一级行业指数中银行、医药、轻工制造、电力及 公用事业、农林牧渔行业指数距离 250 日新高较近，煤炭、石油石化、 房地产、食品饮料、电力设备及新能源行业指数距离 250 日新高较远。 概念指数中，万得微盘股日频等权、数字货币、银行、银行精选、万得 全 A 等权、创新药等概念指数距离 250 日新高较近。 风险提示：市场环境变动风险，模型失效风险，本报告基于历史客观数据统 计，不构成任何投资建议，历史股价表现不代表未来股价表现。 见微知著：利用创新高个股进行市场监测：截至 2025 年 6 月 6 日，共 777 只股票在过去 20 个交易日间创出 250 日新高。其中创新高个股数量最多的 是基础化工、机械、 ...

高技术制造业宏观周报 国信周频高技术制造业扩散指数小幅走弱 证券研究报告 | 2025年06月06日 高技术制造业政策动向上，6 月 3 日，工信部专题研究部署推动人工智 能产业发展和赋能新型工业化，强调要夯实产业基础，强化算力供给， 统筹布局通用大模型和行业专用大模型，注重软硬件适配，加快建立高 质量行业数据集，提升重点产品装备的智能化水平 高技术制造业前沿动态上，6 月 5 日，据 The Information 报道，亚马 逊正开发类人机器人软件，这些机器人或取代快递员，此举旨在推进其 全球包裹投递业务自动化。知情人士透露，亚马逊于旧金山办公室内打 造"人形机器人园区"，作为室内障碍训练场以测试机器人，当前该园 区处于收尾阶段，即将开展测试。其自研人工智能软件为机器人供能， 且计划测试时采用其他公司硬件，初始训练场仅咖啡店大小。 风险提示：高技术制造业发展和结构调整带来指标失灵；经济政策和产业政 策干预；经济增速下滑。 核心观点 经济研究·宏观周报 | 证券分析师：邵兴宇 | 证券分析师：董德志 | | | --- | --- | --- | | 010-88005483 | 021-60933158 ...

Core Viewpoint - The case of Luo Mingchi, former president of Tianjin University of Traditional Chinese Medicine Second Affiliated Hospital, highlights the ongoing corruption issues within the medical industry, as he was sentenced to ten years and six months in prison for accepting bribes totaling approximately 11.74 million yuan [1][4][9]. Group 1: Case Details - Luo Mingchi was found guilty of accepting bribes from various sources, including pharmaceutical companies, private hospitals, and his subordinates, with a total of 28 instances of bribery documented [1][5]. - The court determined that the bribes were particularly large, constituting a serious violation of the law, and emphasized the need for accountability among medical institution managers [4][9]. - The largest single bribe came from a relative, amounting to over 6 million yuan, which accounted for more than half of the total bribes received [7][8]. Group 2: Implications for the Industry - The case serves as a warning to the medical industry about the consequences of corruption, reinforcing the government's "zero tolerance" stance on such practices [9]. - Legal experts suggest that the case reflects broader issues of corruption in the medical field, indicating a need for improved internal and external oversight mechanisms [9][10]. - The ongoing anti-corruption efforts in the medical sector are seen as essential for ensuring public health rights and promoting high-quality development within the industry [9].

| | 研究院副副 | 福岡市 | | | | | | | | --- | --- | --- | --- | --- | --- | --- | --- | --- | | | 15:0 | CENSE CORPI | | | | | | | | | EMIS 9制的 | 000558880 | | | 智能在线网址：彩金利用网登录登录 彩票网址官网 | | | GIOULE GAMERS O | | A | 1805 | 0351 1950 374,2500 | | | | | | | | 2017 | 品番組 | CEO TRUD | | | | | | | | 25-32 | TERE | CBS33355 | | CATALOW | | | | | | | 加 | SED. JA229 | | | | | | | | | 品是本站 | 503 1000 | | | | | | | | | 113 | 289 920.00 | | 05 00 11 | | | | | | પાટ ગુ | 118248 | 22500 | | | | | | | | | 800 | SERVE | | GENERA ...

Investment Rating - The industry investment rating is "Overweight" [2] Core Insights - The report highlights the ongoing active research in life sciences and the global wave of biotechnology revolution, which is accelerating integration into economic and social development, providing new solutions to major challenges such as health, climate change, resource security, and food security. The National Development and Reform Commission has issued the "14th Five-Year Plan for Bioeconomic Development," indicating a trillion-yuan market potential in the bioeconomy [5][12]. Summary by Sections 1. Industry Market Performance - The synthetic biology sector saw an increase of 1.13% in the week of May 26 to May 30, 2025, outperforming the Shanghai Composite Index by 1.16% and the ChiNext Index by 2.53% [6][20]. 2. Company Business Progress - Shanghai Puranwei and the Shanghai Academy of Agricultural Sciences signed a strategic cooperation agreement to develop mycelium leather technology, aiming to create a new type of biological material to replace traditional leather [26]. - Angel Yeast announced a 230 million yuan investment in a project focused on serum-free cell culture medium technology, marking its entry into the synthetic biology sector [26]. - Xiangsheng Technology unveiled its Shanghai product headquarters, focusing on the large-scale application of bio-based materials like FDCA and PEF [27]. 3. Industry Financing Tracking - The report notes an acceleration in financing for synthetic biology companies, with nearly a hundred companies completing new financing rounds since the beginning of 2025 [37]. - Haobo Pharmaceutical completed a $50 million B+ round of financing to advance its antisense oligonucleotide drug AHB-137 for chronic hepatitis B [37]. - Swiss biotechnology company GlycoEra raised $130 million in a B round to develop its IgG4-targeting protein degradation agents [37].